Annual Congress Barcelona 2010

Saturday, 18.09.2010
Sunday, 19.09.2010
Monday, 20.09.2010
Tuesday, 21.09.2010
Wednesday, 22.09.2010

Citations should be made in the following way: Authors. Title. Eur Respir J 2010; 36: Suppl. 54, abstract number.

Material from 2010:

4910 Abstracts
646 Slide presentations
250 Webcasts
97 Handouts
2124 e-posters
250 Multimedia files

Material from 2010: Show

Present and future medical management of pulmonary arterial hypertension

Oral Presentation
Chairs: M. Humbert (Clamart, France), A. Vonk Noordegraaf (Amsterdam, Netherlands)

Download all media

A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension W. Jacobs, A. Boonstra, M. Brand, D. Rosenberg, B. Schaaf, A. Vonk (Amsterdam, Netherlands; Allschwill, Switzerland; Offenbach am Main, Germany)
Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil L. Harnisch, P. Chanu, K. Dykstra, L. Claret, R. Bruno, X. Gao (Sandwich, United Kingdom; St. Louis, New London, United States Of America)
In pulmonary hypertension changes in right ventricular ejection fraction better predict mortality than changes in pulmonary vascular resistance M. van de Veerdonk, J. Marcus, N. Westerhof, A. Vonk-Noordegraaf (Amsterdam, Netherlands)
Outcomes of a phase II study of ACT-293987, an oral IP receptor agonist, in pulmonary arterial hypertension (PAH) I. Lang, A. Torbicki, M. Hoeper, M. Delcroix, K. Karlocai, N. Galiè, G. Simonneau (Vienna, Austria; Warsaw, Poland; , Germany; Leuven, Belgium; Budapest, Hungary; Bologna, Italy; Clamart, France)
Long term use of imatinib in patients with severe pulmonary arterial hypertension H. A. Ghofrani, N. W. Morrell, M. M. Hoeper, H. Olschewski, A. J. Peacock, R. J. Barst, S. Shapiro, D. A. Quinn, S. Pascoe (Hannover, Germany; Cambridge, Glasgow, United Kingdom; Graz, Austria; New York, Los Angeles, Cambridge, United States Of America; Basel, Switzerland)
Relationship between mean pulmonary artery pressure at rest and on mild exercise in subjects aged < 50 years and free of pulmonary hypertension K. Whyte, P. Herve, S. Hoette, X. Jais, O. Sitbon, G. Simonneau, M. Humbert, D. Chemla (Clamart, Bicetre, France)
The progression towards pulmonary arterial hypertension is attenuated by bosentan in scleroderma patients G. Kovacs, R. Maier, E. Aberer, M. Brodmann, W. Graninger, X. Kqiku, S. Scheidl, N. Troester, C. Hesse, L. Rubin, H. Olschewski (Austria; San Diego, United States Of America)
The PPAR-β/δ agonist GW0742 reverses right venticular hypertrophy in a chronically hypoxic rat model of pulmonary hypertension A. Reed, L. Bailey, H. Gashaw, L. Zhao, J. Mitchell, J. Mitchell (London, United Kingdom)